Droperidol for sedation is an antiemetic option during moderate sedation, most often reached for when a patient has not responded to a first-line agent or has a history that favors it. It also carries mild sedative properties of its own.
Dosage:
Initial dose: 1.25-2.5 mg via IM or slow IV
Additional doses: Additional 1.25 mg doses may be administered to achieve the desired effect
Onset of action: 3-10 minutes
Peak effect: 30 minutes
Duration of effect: 120-240 minutes
⚠ FDA boxed warning: droperidol can cause QT prolongation and torsades de pointes, including at or below recommended doses. Screen for QT-prolongation risk and use ECG monitoring per facility policy.
Reversal Agent:
None
Droperidol in Moderate Sedation
The FDA boxed warning on QT prolongation is why droperidol is not a default first choice: before it is given, check the patient’s history and, where facility policy calls for it, a baseline ECG for QT-prolongation risk factors — electrolyte abnormalities, other QT-prolonging drugs, or a personal or family history of arrhythmia. ECG monitoring continues through its two-to-four-hour duration, longer than most of the sedation medications it is paired with, and any new dysrhythmia gets the patient re-evaluated before another dose. There is no reversal agent; recovery is monitored, not reversed. As with any medication given during moderate sedation, administration follows the facility’s sedation policy and the provider’s scope of practice.
Educational reference for sedation providers, relocated from the previous version of this site — not a substitute for the current package insert, your facility protocols, or clinical judgment. Verify all doses against current references before clinical use.